Ischemia modified albumin detection kit and method
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ZYBIO INC
- Filing Date
- 2024-11-27
- Publication Date
- 2026-05-29
AI Technical Summary
Existing ischemia-modified albumin detection kits have shortcomings in terms of stability, precision, and linear range. Furthermore, commonly used stabilizers such as DTT and erythritol pose safety risks and are costly, which hinders their widespread clinical application.
The reagent kit is designed as a liquid dual-reagent kit. Reagent 1 contains divalent cobalt ions and a surfactant, while reagent 2 contains dithiothreitol and a reducing agent. By using a reasonable pH value and component ratio, combined with nonionic surfactants and buffer solutions, the stability and precision of the reagents are improved. Tartaric acid is used as a reducing agent for DTT to enhance stability and precision.
The kit achieved a reactivity deviation of no more than 1% after 7 days of heat acceleration at 37℃, a clinical deviation of no more than 5% after 30 days of opening, and a linear range of 20–180 U/mL, meeting clinical testing needs and showing good clinical relevance with mainstream manufacturers.
Smart Images
Figure CN122108983A_ABST